Disease · MONDO_0005002
Comparisons in its trials417
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 417
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
Tiotropium + Olodaterol Cohort - Propensity Score Matched vs Inhaled Corticosteroids (ICS) + Long-acting ß2 Agonists (LABA) Cohort - Propensity Score Matched: Number of Subjects With Event First Moderate or Severe COPD Exacerbations After Index Date | 424 of 3,752 | 375 of 3,752 | 7,504 | NCT05402020 | Trial comparisons |
Tiotropium + Olodaterol Cohort - Propensity Score Matched vs Inhaled Corticosteroids (ICS) + Long-acting ß2 Agonists (LABA) Cohort - Propensity Score Matched: Number of Subjects With Event First Hospitalization for Community-acquired Pneumonia After Entry | 11 of 3,752 | 11 of 3,752 | 7,504 | NCT05402020 | Trial comparisons |
Tiotropium + Olodaterol Cohort - Propensity Score Matched vs Inhaled Corticosteroids (ICS) + Long-acting ß2 Agonists (LABA) Cohort - Propensity Score Matched: Number of Subjects With Event Triple Therapy Escalation After Index Date | 122 of 3,752 | 153 of 3,752 | 7,504 | NCT05402020 | Trial comparisons |
| Tiotropium vs Salmeterol: serious adverse events | 545 of 3,707 | 606 of 3,669 | 7,376 | NCT00563381 | Trial comparisons |
| FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation | 200 of 1,078 | 674 of 2,923 | 4,001 | NCT01337336 | Trial comparisons |
| Tiotropium vs Placebo: serious adverse events | 342 of 1,952 | 336 of 1,965 | 3,917 | NCT00387088 | Trial comparisons |
| Tiotropium vs Placebo: Number of Patients With at Least One Hospitalisation for a COPD Exacerbation | 161 of 1,939 | 198 of 1,953 | 3,892 | NCT00387088 | Trial comparisons |
| Tiotropium vs Placebo: Number of Patients With at Least One COPD Exacerbation | 685 of 1,939 | 842 of 1,953 | 3,892 | NCT00387088 | Trial comparisons |
| Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) - on Study Analysis | 69 of 1,791 | 76 of 1,798 | 3,589 | NCT01966107 | Trial comparisons |
| Aclidinium Bromide vs Placebo: Number of Participants With Major Adverse Cardiovascular Event (MACE) or Other Serious Cardiovascular Events of Interest - On-study Analysis | 168 of 1,791 | 160 of 1,798 | 3,589 | NCT01966107 | Trial comparisons |
| Aclidinium Bromide vs Placebo: deaths from any cause | 75 of 1,791 | 64 of 1,798 | 3,589 | NCT01966107 | Trial comparisons |
| Aclidinium Bromide vs Placebo: serious adverse events | 409 of 1,791 | 356 of 1,798 | 3,589 | NCT01966107 | Trial comparisons |
| IndIndacaterol vs Tiotropium: serious adverse events | 263 of 1,721 | 255 of 1,718 | 3,439 | NCT00845728 | Trial comparisons |
| QVA149 vs Long Acting B2 Agonist (LABA) and Inhaled Corticosteroid (ICS): serious adverse events | 308 of 1,678 | 334 of 1,680 | 3,358 | NCT01782326 | Trial comparisons |
| FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: deaths from any cause | 8 of 1,545 | 8 of 1,547 | 3,092 | NCT03467425 | Trial comparisons |
| FF /UMEC/VI: 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI vs Non-Ellipta MITT: serious adverse events | 114 of 1,545 | 114 of 1,547 | 3,092 | NCT03467425 | Trial comparisons |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to an Event of Discontinuation of Initial Therapy Occurring in a Year | 374 of 1,396 | 219 of 1,403 | 2,799 | NCT01551758 | Trial comparisons |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to the First Serious Adverse Event of Pneumonia Occuring in a Year | 89 of 1,396 | 80 of 1,403 | 2,799 | NCT01551758 | Trial comparisons |
| FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Non-serious Adverse Drug Reactions (ADR) | 192 of 1,396 | 88 of 1,403 | 2,799 | NCT01551758 | Trial comparisons |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year | 852 of 1,396 | 943 of 1,403 | 2,799 | NCT01551758 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005002/comparisons